Recent news on

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  Apr 25, 2007
WebWire (press release),Genzyme’s Hectorol® (doxercalciferol) is already indicated for patients with earlier stages of chronic kidney disease, as well as those on dialysis.

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  26 Apr 2007
WebWire (press release),Genzyme’s Hectorol® (doxercalciferol) is already indicated for patients with earlier stages of chronic kidney disease, as well as those on dialysis.

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ...  -  Jan 10, 2007
Oxfordshire Bioscience Network (press release),...and Hectorol® (doxercalciferol), a line of Vitamin D2 products for secondary hyperparathyroidism in dialysis patients and those with earlier stages of

Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, and Hectorol® (doxercalciferol), a line of ... -Yahoo! News (press release) Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
Renagel(R) (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, and Hectorol(R) (doxercalciferol), a line ... -Drug Newswire (press release), American Kidney Fund, Genzyme Announce New Medicare Part D ...  Jul 31, 2006
...the two organizations launched the Renagel Patient Assistance ProgramSM (RPAP), which provides access to Renagel and Hectorol® (doxercalciferol) for those not ... -WebWire

Delivers Solid Earnings Growth Based on Strong Top-Line ...  Jul 18, 2006
The expanded US commercial organization is also helping to drive the growth of Hectorol® (doxercalciferol), which treats secondary hyperparathyroidism in ... -Oxfordshire Bioscience Network

Genzyme Reports Second-Quarter Financial Results  Jul 12, 2006
The expanded US commercial organization is also helping to drive the growth of Hectorol(R) (doxercalciferol), which treats secondary hyperparathyroidism in ... -Drug Newswire



Genzyme Reports Financial Results for the First Quarter of 2006  Apr 19, 2006
Sales of Fabrazyme(R) (agalsidase beta), Synvisc(R) (hylan GF 20) and Hectorol(R) (doxercalciferol) experienced sequential growth below Genzyme's expectations ... - MSN Money

Genzyme Reports Financial Results for the First Quarter of 2006  Apr 19, 2006
Sales of Fabrazyme® (agalsidase beta), Synvisc® (hylan GF 20) and Hectorol® (doxercalciferol) experienced sequential growth below Genzyme's expectations ... - Yahoo! News

Genzyme's First-Quarter Sales Below Expectations  Apr 19, 2006
...levels were Fabrazyme (agalsidase beta) for Fabry's disease, Synvisc (hylan GF 20) for osteoarthritic knee pain, and Hectorol (doxercalciferol) for secondary ... - BioWorld Online (subscription)



Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue  Jan 9, 2006
Both Renagel and Genzyme's Hectorol(R) (doxercalciferol)are positioned favorably on most of the Part D prescription drug plans now available to Medicare ... - MSN Money

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional